Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab in Moderate-to-severe Atopic Dermatitis
NCT05398445Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started May 2022; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05398445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398445.